Giuseppe Ferrauto
Overview
Explore the profile of Giuseppe Ferrauto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scarciglia A, Papi C, Romiti C, Leone A, Di Gregorio E, Ferrauto G
Glob Chall
. 2025 Mar;
9(3):2400269.
PMID: 40071223
Gadolinium-based contrast agents (GBCAs) have revolutionized medical imaging, enhancing the accuracy and diagnostic value of magnetic resonance imaging (MRI). The increasing use of GBCAs has raised concerns about the release...
2.
Cavallari E, Lorenzi E, Di Gregorio E, Ferrauto G, Aime S, Vallortigara G, et al.
J Cereb Blood Flow Metab
. 2024 Dec;
:271678X241309783.
PMID: 39719068
This study presents the first in vivo measurement of transcytolemmal water exchange in the brain using a novel Magnetic Resonance technique. We extend previous applications of Chemical Exchange Saturation Transfer...
3.
Rosa E, Di Gregorio E, Ferrauto G, Diaferia C, Gallo E, Terreno E, et al.
J Mater Chem B
. 2024 Jun;
12(26):6371-6383.
PMID: 38864345
The self-assembly of peptides and peptide analogues may be exploited to develop platforms for different biomedical applications, among which CEST-MRI (chemical exchange saturation transfer magnetic resonance imaging) represents one of...
4.
Di Gregorio E, Scarciglia A, Amaolo A, Ferrauto G
Nanoscale Adv
. 2024 Feb;
6(3):777-781.
PMID: 38298593
Here we propose innovative photoacoustic imaging (PAI) contrast agents, based on the loading of Mn(iii)-, Fe(iii)- or Zn(ii)-protoporphyrin IX in serum albumin. These systems show different absorption wavelengths, opening the...
5.
Stefania R, Palagi L, Di Gregorio E, Ferrauto G, Dinatale V, Aime S, et al.
J Am Chem Soc
. 2023 Dec;
146(1):134-144.
PMID: 38152996
Gd-L1 is a macrocyclic Gd-HPDO3A derivative functionalized with a short spacer to a trisulfonated pyrene. When compared to Gd-HPDO3A, the increased relaxivity appears to be determined by both the higher...
6.
Grea T, Jacquot G, Durand A, Mathieu C, Gasser A, Zhu C, et al.
Adv Mater
. 2023 Dec;
36(13):e2308738.
PMID: 38105299
Subcutaneous (SC) administration of monoclonal antibodies (mAbs) is a proven strategy for improving therapeutic outcomes and patient compliance. The current FDA-/EMA-approved enzymatic approach, utilizing recombinant human hyaluronidase (rHuPH20) to enhance...
7.
Di Gregorio E, Papi C, Conti L, Di Lorenzo A, Cavallari E, Salvatore M, et al.
Angew Chem Int Ed Engl
. 2023 Oct;
63(6):e202313485.
PMID: 37905585
Water cycling across the membrane transporters is considered a hallmark of cellular metabolism and it could be of high diagnostic relevance in the characterization of tumors and other diseases. The...
8.
Di Gregorio E, Rosa E, Ferrauto G, Diaferia C, Gallo E, Accardo A, et al.
J Mater Chem B
. 2023 Jul;
11(31):7435-7441.
PMID: 37435712
Peptide-based hydrogels have been recently investigated as materials for biomedical applications like tissue engineering and delivery of drugs and imaging agents. Among the synthetic peptide hydrogelators, the cationic hexapeptides Ac-K1...
9.
Di Gregorio E, Romiti C, Di Lorenzo A, Cavallo F, Ferrauto G, Conti L
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612006
Breast cancer is the leading cause of cancer-related death in women. Although many therapeutic approaches are available, systemic chemotherapy remains the primary choice, especially for triple-negative and advanced breast cancers....
10.
Di Lorenzo A, Bolli E, Ruiu R, Ferrauto G, Di Gregorio E, Avalle L, et al.
Oncoimmunology
. 2022 Jun;
11(1):2086752.
PMID: 35756841
Cancer stem cells (CSCs) are the main drivers of disease progression and chemotherapy resistance in breast cancer. Tumor progression and chemoresistance might then be prevented by CSC-targeted therapies. We previously...